Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Economic evaluation of recombinant human copper zinc superoxide dismutase administered at birth to premature infants

Abstract

Objective:

To determine the cost-effectiveness of recombinant human superoxide dismutase (rhSOD) in the prevention of chronic respiratory morbidity, defined as use of respiratory medications, in preterm infants.

Study Design:

This retrospective economic evaluation was undertaken using data from a previously published randomized controlled trial of the use of rhSOD in neonates of birthweight 600 to 1200 g. This ancillary study measured all relevant direct medical costs from birth to 1 year corrected age using resource data collected for infants from the clinical trial. Unit costs were derived from secondary datasets in similar populations, stratified by level of care or diagnosis. All costs were expressed in 2003 US dollars.

Result:

rhSOD was associated with a highly favorable incremental cost of only $378 per chronic respiratory morbidity averted at 1 year corrected age. There was a 95% probability that the therapy would be considered cost-effective if a decision maker was willing to pay $7000 to avert one infant with long-term significant respiratory illness, and a 52% probability that it would actually reduce costs while improving outcomes. These results were more pronounced among infants <27 weeks gestational age at birth.

Conclusion:

Based on resource data from a single randomized trial, this retrospective analysis supports the potential economic desirability of rhSOD treatment in this population.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Kinsella JP, Greenough A, Abman SH . Bronchopulmonary dysplasia. Lancet 2006; 367: 1421–1431.

    Article  Google Scholar 

  2. Waitzman NJ, Rogowski J . Societal costs of preterm birth. In: Behrman R, Stith-Butler A (eds). Preterm Birth: Causes, Consequences and Prevention. The National Academic Press: Washington, D.C., 2006, pp 398–429.

    Google Scholar 

  3. Rogowski J . Cost-effectiveness of care for very low birth weight infants. Pediatrics 1998; 102: 35–43.

    Article  CAS  Google Scholar 

  4. Smith VC, Zupancic JA, McCormick MC, Croen LA, Greene J, Escobar GJ et al. Rehospitalization in the first year of life among infants with bronchopulmonary dysplasia. J Pediatr 2004; 144: 799–803.

    PubMed  Google Scholar 

  5. Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W . Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics 2003; 111: 469–476.

    Article  Google Scholar 

  6. Center for Medicare and Medicaid Services. Hospital Cost Report, Fiscal Years 1996–Current 2006 [updated 2006 April 12, 2006; cited]; Available from: http://www.cms.hhs.gov/CostReports/02_HospitalCostReport.asp.

  7. Red Book: Pharmacy's Fundamental Reference. Thomson PDR: Montvale, NJ, 2006.

  8. HCUP Kids’ Inpatient Database (KID). Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality: Rockville, MD, 2003 [updated 2003; cited]; Available from: www.hcup-us.ahrq.gov/kidoverview.jsp.

  9. RBRVS: What is it and how does it affect pediatrics? American Academy of Pediatrics 2007 [updated 2007; cited 2006 December 20, 2006]; Available from: http://practice.aap.org/content.aspx?aID=652.

  10. Consumer Price Index (Medical Care, all Urban Consumers, Northeast Urban) National Bureau of Labor Statistics 2006 [updated 2006; cited 2006 July 1]; Available from: http://www.bls.gov/cpi/.

  11. Briggs AH, Wonderling DE, Mooney CZ . Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6: 327–340.

    Article  CAS  Google Scholar 

  12. Efron B, Tibshirani RJ . An Introduction to the Bootstrap. Chapman and Hall/CRC: New York, 1993.

    Book  Google Scholar 

  13. Fenwick E, Claxton K, Sculpher M . Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001; 10: 779–787.

    Article  CAS  Google Scholar 

  14. Petrou S, Bischof M, Bennett C, Elbourne D, Field D, McNally H . Cost-effectiveness of neonatal extracorporeal membrane oxygenation based on 7-year results from the United Kingdom Collaborative ECMO Trial. Pediatrics 2006; 117: 1640–1649.

    Article  Google Scholar 

  15. Lorch SA, Cnaan A, Barnhart K . Cost-effectiveness of inhaled nitric oxide for the management of persistent pulmonary hypertension of the newborn. Pediatrics 2004; 114: 417–426.

    Article  Google Scholar 

  16. Keren R, Helfand M, Homer C, McPhillips H, Lieu TA . Projected cost-effectiveness of statewide universal newborn hearing screening. Pediatrics 2002; 110: 855–864.

    Article  Google Scholar 

  17. Backhouse ME, Mauskopf JA, Jones D, Wold DE, Schumacher R, Cotton R et al. Economic outcomes of colfosceril palmitate rescue therapy in infants weighing 1250 g or more with respiratory distress syndrome: results from a randomised trial. Pharmacoeconomics 1994; 6: 358–369.

    Article  CAS  Google Scholar 

  18. Wang LY, Zhong Y, Wheeler L . Direct and indirect costs of asthma in school-age children. Prev Chronic Dis 2005; 2: A11.

    PubMed  Google Scholar 

  19. Smith DH, Malone DC, Lawson KA, Okamoto LJ, Battista C, Saunders WB . A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997; 156: 787–793.

    Article  CAS  Google Scholar 

  20. Parad R, Allred E, Rosenfeld W, Davis J, The North American rhSOD Study Group. Incidence and severity of retinopathy of prematurity (ROP) is reduced in extremely low gestational age (GA) newborns (ELGANS) treated with recombinant human Cu/Zn superoxide dismutase (rhSOD) [Abstract]. Pediatric Academic Societies. (http://www.pas-meeting.org/2009Baltimore/abstract_archives.asp) 2007; 8225: 6.

    Google Scholar 

  21. Fenwick E, O’Brien BJ, Briggs A . Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. Health Econ 2004; 13: 405–415.

    Article  Google Scholar 

  22. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds). Cost-Effectiveness in Health and Medicine. Oxford University Press: New York, 1996.

    Google Scholar 

  23. Smith VC, Zupancic JA, McCormick MC, Croen LA, Greene J, Escobar GJ et al. Trends in severe bronchopulmonary dysplasia rates between 1994 and 2002. J Pediatr 2005; 146: 469–473.

    Article  Google Scholar 

  24. O’Brien B . Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials? Med Care 1996; 34: DS99–D108.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to J A F Zupancic.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McBride, J., Parad, R., Davis, J. et al. Economic evaluation of recombinant human copper zinc superoxide dismutase administered at birth to premature infants. J Perinatol 29, 364–371 (2009). https://doi.org/10.1038/jp.2008.225

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jp.2008.225

Keywords

Search

Quick links